ABCG2 and cancer: Several receptor tyrosine kinase inhibitors (RTKIs) have been reported to interact strongly with ABCB1 and/or ABCG2 and reverse multidrug resistance in cancer cells overexpressing ABCB1 and/or ABCG2 [17,18,29].